



Les Pensières Center for Global Health

Veyrier-du-Lac – France

May 8-19, 2023

EACCME® Accreditation of event ref.

#LEE22-01851

## FINAL COURSE PROGRAM

### Organized by

---

The Mériem Foundation and  
the University of Geneva

### With the co-sponsorship of

---

- Africa Centres for Disease Control and Prevention
- Bill & Melinda Gates Foundation
- Centers for Disease Control and Prevention (CDC)
- Coalition for Epidemic Preparedness Innovations (CEPI)
- European Centre for Disease Prevention and Control (ECDC)
- European & Developing Countries Clinical Trials Partnership (EDCTP)
- European Society for Paediatric Infectious Diseases (ESPID)
- Johns Hopkins Bloomberg School of Public Health
- International Pediatric Association
- National Foundation for Infectious Diseases (NFID)
- National Institutes of Health (NIH/NIAID-USA) and Fogarty International Center
- World Health Organization



**UNIVERSITÉ  
DE GENÈVE**



## MONDAY 08 MAY 2023

09:00	<b>Opening and objectives of the course</b>	<b>Kamel Senouci</b> , Director, ADVAC, University of Geneva
09:30	<b>Administrative briefing</b>	<b>Bénédicte Pansier</b> , Director, Les Pensières Center for Global Health, Fondation Mérieux
<b>SESSION 1a - THE MULTIFACETED NATURE OF VACCINOLOGY</b>		<b>Chair: Adam Finn</b> , University of Bristol, UK
09:40-10:05	<b>How to implement and roll-out a new program of immunization</b>	<b>Pradeep Haldar</b> , Strategic Advisor, John Snow, Inc. (JSI), India
10:05-10:25	Discussion	
10:25-10:55	Break	
10:55-11:20	<b>Access to vaccination in Gavi-eligible countries and at global level</b>	<b>Aurelia Nguyen</b> , Gavi, The Vaccine Alliance, Geneva
11:20-11:40	Discussion	
11:40-11:50	Time for students to reflect personally on the learnings of the morning	
11:50-13:20	Lunch	
13:20-13:45	<b>A global perspective on the regulation of vaccines</b>	<b>Norman Baylor</b> , Biologics Consulting Inc., USA
13:45-14:05	Discussion	
14:05-14:30	<b>Impact of vaccination on disease epidemiology</b>	<b>Roy Anderson</b> , London Centre for Neglected Tropical Disease Research, Imperial College, UK
14:30-14:50	Discussion	
14:50-15:20	Break	
15:20-16:50	<b>Session 1b: Special lectures from Industry</b>	
16:50-17:00	Time for students to reflect personally on the learnings of the afternoon	
17:00-19:00	<b>Self-presentation of individual participants (background, interests in life...) &amp; Welcome reception</b>	

## TUESDAY 9 MAY 2023

<b>SESSION 2 - HOW VACCINES WORK</b>		<b>Chair: Arnaud Didierlaurent</b> , University of Geneva
09:00-09:25	<b>How are vaccine responses elicited?</b> What a vaccinologist should know about the basic aspects of immunological responses (a) B-cell responses	<b>Claire-Anne Siegrist</b> , University of Geneva
09:25-09:45	Discussion	
09:45-10:15	Break	
10:15-10:40	What a vaccinologist should know about the basic aspects of immunological responses (b) T-cell responses	<b>Claire-Anne Siegrist</b> , University of Geneva
10:40-11:00	Discussion	
11:00-11:25	<b>Use and limitations of correlates of immunity in vaccinology</b>	<b>Andrew Pollard</b> , University of Oxford, UK
11:25-11:45	Discussion	
11:45-11:55	Time for students to reflect personally on the learnings of the morning	
11:55-13:25	Lunch	
13:25-13:50	<b>Vaccines and mucosal immunity</b>	<b>Adam Finn</b> , University of Bristol, UK
13:50-14:10	Discussion	
14:10-14:55	<b>Vaccines and immunological memory</b> Quiz and general discussion	<b>Claire-Anne Siegrist</b> , University of Geneva
14:55-15:25	Break	
15:25-15:50	<b>Immunological memory</b>	<b>Rafi Ahmed</b> , Emory University, USA
15:50-16:10	Discussion	
16:10-16:35	<b>How do vaccines cause adverse events?</b>	<b>Narendra Arora</b> , INCLEN, India
16:35-16:55	Discussion	
16:55-17:05	Time for students to reflect personally on the learnings of the afternoon	
17:05-18:30	<b>Mandatory vs voluntary vaccination</b> a round table debate	<b>Chair: Hanna Nohynek</b> , Finnish Institute for Health and Welfare, Finland <b>Adam Finn</b> , University of Bristol, UK

## WEDNESDAY 10 MAY 2023

<b>SESSION 3 – VACCINE DEVELOPMENT</b>		<b>Chair: Emily Erbelding, Director, DMID, NIH, USA</b>
09:00-09:25	<b>Landscape in vaccine and immunization technologies</b>	<b>Cristina Casetti, NIH-NIAID, USA</b>
09:25-09:45	Discussion	
09:45-10:10	<b>Vaccine adjuvants</b>	<b>Arnaud Didierlaurent, University of Geneva</b>
10:10-10:30	Discussion	
10:30-11:00	Break	
11:00-11:25	<b>From pre-clinical research to vaccine development: Examples of go-no-go decisions</b>	<b>Veronica Gambillara, GlycoEra AG, Switzerland</b>
11:25-11:45	Discussion	
11:45-11:55	Time for students to reflect personally on the learnings of the morning	
11:55-13:25	Lunch	
13:25-15:05	<b>Regulatory considerations</b> A round-table debate	<b>Chair: Emily Erbelding, Director, DMID/NIAID, NIH, USA</b> <b>Norman Baylor, Biologics Consulting Group, Inc., USA, Pieter Neels, Vaccine-advice, Belgium, Saeedeh Fakhrzadeh, Food and Drug Administration, Iran, Ozzie Berger, GSK and David Greenberg, Sanofi</b>
15:05-15:35	Break	
15:35-16:00	<b>The complexity of quality control in vaccine manufacturing</b>	<b>Philippe Juvin, Sanofi Pasteur, Lyon, France</b>
16:00-16:20	Discussion	
16:20-16:30	Time for students to reflect personally on the learnings of the afternoon	
16:30-18:00	<b>Interactive session: From ideas to implementation - the realities of funding for vaccine research and development</b>	<b>Emily Erbelding, DMID, NIH, USA (Chairperson), Veronica Gambillara, GlycoEra AG, Switzerland, Penny Heaton, J&amp;J, and selected ADVAC students</b>

## THURSDAY 11 MAY 2023

<b>SESSION 4 - ASSESSING VACCINES IN CLINICAL TRIALS (I)</b>		<b>Chair: Hanna Nohynek</b> , Finnish Institute for Health and Welfare, Finland
09:00-09:25	<b>Clinical trials: an overview of issues to be considered</b>	<b>Myron Levine</b> , University of Maryland, USA
09:25-09:45	Discussion	
09:45-10:10	<b>Introduction to statistical aspects of clinical trials</b> <b>1- Defining sample size</b>	<b>Peter Smith</b> , London School of Hygiene and Tropical Medicine, UK
10:10-10:30	Discussion	
10:30-10:40	Time for students to reflect personally on the learnings of the first part of the morning	
10:40-11:10	Break	
11:10-13:50	<b>How to design, recruit volunteers for, and analyze the results of selected phase II trials</b> <b>Small group exercise 1:</b> Seven Groups - Themes: Group 1 <i>S. aureus</i> Group 2 Ebola Group 3 Dengue Group 4 RSV Group 5 Monkeypox Group 6 Typhoid conjugate vaccines Group 7 Coronavirus	<b>Facilitators:</b>  <b>Veronica Gambillara</b> <b>Pieter Neels</b> <b>Norman Baylor</b> <b>Romina Libster</b> <b>Kari Johansen</b> <b>Kamel Senouci</b> <b>Emily Erbeling</b>
12:40-13:10 <i>Buffet lunch</i>		
13:50-14:15	<b>Assessing herd protection and vaccine effectiveness (and use for licensure)</b>	<b>John Clemens</b> , Senior Scientific Advisor to the Director General, International Vaccine Institute (IVI), Republic of Korea
14:15-14:35	Discussion	
14:35-15:00	<b>Clinical trials: role of a Data Safety Monitoring Board (DSMB) (with several examples of intervention)</b>	<b>Robert Heyderman</b> , University College London, UK
15:00-15:20	Discussion	
15:20-15:50	Break	
15:50-16:15	<b>Introduction to Human Challenge Trials</b>	<b>Chris Chiu</b> , Imperial College London
16:15-17:10	<b>Dealing with Human Challenge Trials: Panel discussion and questions</b>	<b>Chairperson: Penny Heaton</b> , J&J <b>Joris Vandeputte</b> , IABS, <b>Pieter Neels</b> , Vaccine-advice, Belgium, <b>Chris Chiu</b> , Imperial College London
<b>Special lecture: THE 7<sup>th</sup> LAMBERT LECTURE</b>		
17:10-17:50	<b>Perspectives for CD8+ T cell-based vaccines</b>	<b>Daniel Pinschewer</b> , University of Basel, Switzerland
17:50-18:10	Discussion	
18:10-18:20	Time for students to reflect personally on the learnings of the afternoon	

## FRIDAY 12 MAY 2023

<b>SESSION 5 - VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS</b>		<b>Chair: Kari Johansen, Public Health Agency, Sweden</b>
09:00-09:25	<b>Lessons from previous adverse effects of vaccination and assessment of causal relationships</b>	<b>Madhav Balakrishnan, WHO, Geneva</b>
09:25-09:45	Discussion	
09:45-10:10	<b>Vaccination and immune-mediated diseases</b>	<b>Christiane Eberhardt, University of Geneva</b>
10:10-10:30	Discussion	
10:30-10:50	Break	
10:50-11:15	<b>Population-based post-licensure surveillance</b>	<b>Nick Andrews, Public Health England, UK</b>
11:15-11:35	Discussion	
11:35-11:45	Time for students to reflect personally on the learnings of the morning	
11:45-13:15	Lunch	
13:15-13:40	<b>Thrombotic Thrombocytopenia Syndrome (TTS) following vaccination with COVID-19 non-replicant adenovirus vector-based vaccines</b>	<b>Kawsar Talaat, Johns Hopkins Bloomberg, School of Public Health, Baltimore, USA</b>
13:40-14:00	Discussion	
14:00-14:25	<b>Immunization safety in low- and middle-income country vaccination programs</b>	<b>Philippe Duclos, ADVAC</b>
14:25-14:45	Discussion	
14:45-15:10	<b>Addressing vaccine hesitancy and acceptance</b>	<b>Noni McDonald, Dalhousie University, Halifax, Canada</b>
15:10-15:30	Discussion	
15:30-15:50	Break	
<b>SESSION 6 – ASSESSING VACCINES IN CLINICAL TRIALS (II)</b>		<b>Chair: Hanna Nohynek, Finnish Institute for Health and Welfare, Finland</b>
15:50-16:15	<b>Introduction to statistical aspects of clinical trials 2- Statistical assessment and reporting of phase 3 trials</b>	<b>Peter Smith, LSHTM, UK</b>
16:15-16:35	Discussion	
16:35-18:50	<b>Small group exercise 2: Designing and analyzing the results of selected phase 3 trials</b>  Seven Groups	<b>Facilitators: Nick Andrews, Brad Gessner, Penny Heaton, Kari Johansen, Pieter Neels, Hanna Nohynek, Peter Smith</b>
18:50-19:00	Time for students to reflect personally on the learnings of the afternoon	

<b>SATURDAY 13 MAY 2023</b>		
<b>SESSION 7 - ETHICAL ISSUES</b>		<b>Chair: Kari Johansen, Public Health Agency, Sweden</b>
09:00-09:25	<b>Principles, guidelines and frameworks for ethical considerations in clinical trials of vaccines</b>	<b>Catherine Slack, University of KwaZulu-Natal, South Africa</b>
09:25-09:45	Discussion	
09:45-10:10	<b>Applied ethics in immunization programs and practice</b>	<b>Noni McDonald, Dalhousie University, Halifax, Canada</b>
10:10-10:30	Discussion	
10:30-10:40	Coffee break	
10:40-13:00	<b>Small group exercise 3: Ethical considerations in COVID-19 vaccine trials</b> Seven Groups	Facilitators: <b>Edwin Asturias, Betty Dodet, Noni McDonald, Kari Johansen, Pieter Neels, Catherine Slack, Romina Libster</b>
13:00-13:10	Time for students to reflect personally on the learnings of the morning	
13:10-14:10	Lunch	
14:10-15:40	<b>Parallel sessions (1)</b>  <b>1. AEFI: Causality assessment</b>  <b>2. Monitoring and evaluation of vaccine programs</b>	<b>Madhav Balakrishnan, WHO, Geneva</b>  <b>Carolina Danovaro, WHO, Geneva and Marta Gacic-Dobo, WHO Geneva</b>

<b>MONDAY 15 MAY 2023</b>		
08:50-09:00	<b>Ethical considerations in COVID-19 vaccine trials: Recap</b>	<b>Catherine Slack</b> , University of KwaZulu-Natal, South Africa
<b>SESSION 8 - INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES</b>		<b>Chair: Anna Durbin</b> , Johns Hopkins B. School of Public Health, Baltimore, USA
09:00-09:25	<b>Disease burden and the public health value of vaccines</b>	<b>Annelies Wilder-Smith</b> , Consultant, WHO (VIA ZOOM)
09:25-09:45	Discussion	
09:45-10:10	<b>Health economics (including modelling) as a tool in analyzing vaccine policy options</b>	<b>Ramanan Laxminarayan</b> , One Health Trust (OHT), USA
10:10-10:30	Discussion	
10:30-11:00	Break	
11:00-11:25	<b>Non-specific effects of vaccines</b>	<b>Nigel Curtis</b> , The Royal Children's Hospital, Melbourne, Australia
11:25-11:45	Discussion	
11:45-11:55	Time for students to reflect personally on the learnings of the morning	
11:55-13:25	Lunch	
13:25-13:50	<b>Dengue vaccines</b>	<b>Anna Durbin</b> , Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
13:50-14:10	Discussion	
14:10-14:35	<b>Response to polysaccharide and conjugate vaccines</b>	<b>David Goldblatt</b> , University College London, UK
14:35-14:55	Discussion	
14:55-15:25	Break	
15:25-16:05	<b>Pneumococcal conjugate vaccines: Efficacy and limitations of available vaccines and existing and potential vaccination strategies</b>	<b>Ron Dagan</b> , Soroka Medical Center, Beer Sheva, Israel <b>Keith Klugman</b> , Bill & Melinda Gates Foundation, USA
16:05-16:35	Discussion	
16:35-17:00	<b>Challenges and solutions in making evidence-based national vaccination policies and recommendations</b>	<b>Philippe Duclos</b> , ADVAC
17:00-17:20	Discussion	
17:20-19:20	<b>Small group exercise 4: Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness</b> <b>Part 1: Preparation and data analysis</b> Group 1 Rotavirus Group 2 HPV Group 3 Coronavirus LMIC Group 4 Coronavirus HIC Group 5 Malaria Group 6 Shingles Group 7 RSV	Facilitators: <b>Umesh Parashar</b> <b>Kamel Senouci</b> <b>Brad Gessner &amp; Hanna Nohynek</b> <b>Kari Johansen</b> <b>Kathy Neuzil</b> <b>Keipp Talbot</b> <b>Janet Englund</b>
19:20-19:30	Time for students to reflect personally on the learnings of the afternoon	



# TUESDAY 16 MAY 2023

## SESSION 8 (Ctd) - INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES

Chair: Anna Durbin, Johns Hopkins B. School of Public Health, Baltimore, USA

08:30-08:55	<b>HPV vaccines</b>	<b>Margaret Stanley</b> , Cambridge University, UK (VIA ZOOM)
08:55-09:15	Discussion	
09:15-09:40	<b>Vaccine responses and efficacy in the elderly</b>	<b>Keipp Talbot</b> , Vanderbilt University, USA
09:40-10:00	Discussion	
10:00-10:25	Break	
10:25-10:50	<b>Meningococcal vaccines</b>	<b>Shamez Ladhani</b> , Public Health England, UK
10:50-11:10	Discussion	
11:10-11:35	<b>Pathogen evolution and population immunity: methods and applications for vaccine development and policy</b>	<b>Martin Maiden</b> , University of Oxford, UK
11:35-11:55	Discussion	
11:55-12:05	Time for students to reflect personally on the learnings of the morning	
12:05-13:35	Lunch	
13:35-14:00	<b>Success and challenges with rotavirus and norovirus vaccines</b>	<b>Umesh Parashar</b> , Centers for Disease Control, Atlanta, USA
14:00-14:20	Discussion	
14:20-14:45	<b>Cancer vaccines</b>	<b>Patrick Ott</b> , Harvard University, USA
14:45-15:05	Discussion	
15:05-15:35	Break	
15:35-16:35	<b>Small group exercise 4: Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness</b> <b>Part 2: Presentations, discussion and conclusions</b> Group 1 Rotavirus Group 2 HPV Group 3 Coronavirus LMIC Group 4 Coronavirus HIC Group 5 Malaria Group 6 Shingles Group 7 RSV	Facilitators: <b>Umesh Parashar</b> <b>Kamel Senouci</b> <b>Brad Gessner &amp; Hanna Nohynek</b> <b>Kari Johansen</b> <b>Kathy Neuzil</b> <b>Keipp Talbot</b> <b>Janet Englund</b>
16:35-17:00	<b>COVID Vaccines</b>	<b>Melanie Saville</b> , CEPI, UK
17:00-17:20	Discussion	
17:20-17:30	Time for students to reflect personally on the learnings of the afternoon	
17:40	Soccer game North vs South of the World	
19:30	<b>Alumni session</b> <b>Bill &amp; Melinda Gates Foundation's perspective on immunization</b> <b>Impact of ADVAC and vision on future of vaccinology; alumni presentations:</b>	<b>Violaine Mitchell</b> , Director Immunization, Bill & Melinda Gates Foundation <b>Deepa Gamage</b> , Ministry of Health, Sri Lanka and <b>Romina Libster</b> , Fundación INFANT/ National Scientific and Technical Research Council/ Vanderbilt University

<b>WEDNESDAY 17 MAY 2023</b>		
<b>SESSION 9 - SELECTING APPROPRIATE VACCINATION STRATEGIES</b>		<b>Chair: Janet Englund</b> , Children's Hospital and Regional Medical Center, Seattle, USA
09:00-09:25	<b>Vaccination and pregnancy: Scientific basis, main issues and applications</b>	<b>Janet Englund</b> , Children's Hospital and Regional Medical Center, Seattle, USA
09:25-09:45	Discussion	
09:45-10:10	<b>Vaccination in early life</b>	<b>Christiane Eberhardt</b> , University of Geneva
10:10-10:30	Discussion	
10:30-11:00	Break	
11:00-11:25	<b>Vaccination schedules: Past, present and future - is there some rationale?</b>	<b>Edwin Asturias</b> , Children's Hospital Colorado, USA
11:25-11:45	Discussion	
11:45-12:10	<b>Influenza biology, new vaccines and vaccination strategies for different age groups</b>	<b>Kathy Neuzil</b> , Center for Vaccine Development, University of Maryland, Baltimore, USA
12:10-12:30	Discussion	
12:30-12:40	Time for students to reflect personally on the learnings of the morning	
12:40-13:10	Buffet lunch	
13:10-15:40	<b>Parallel sessions (2)</b>	
	1.National decision-making for immunization programmes	<b>Christoph Steffen</b> , WHO & <b>Kamel Senouci</b> , University of Geneva
	2.Clinical vaccinology: patients' problem solving	<b>Alessandro Diana</b> , University of Geneva and <b>Christiane Eberhardt</b> , University of Geneva
	3. New approaches towards vaccination e-registries	<b>Julia Stowe</b> , Public Health England, UK, <b>Carolina Danovaro</b> , WHO Geneva, and <b>Kari Johansen</b> , Public Health Institute, Sweden
	4. Cold Chain management	<b>Souleymane Kone</b> , WHO Geneva and <b>Collins Tabu</b> , Immunization Manager, Kenya
15:40-16:00	Break	
16:00-16:25	<b>Vaccination in immuno-compromised individuals, including HIV positive patients</b>	<b>Janet Englund</b> , Children's Hospital and Regional Medical Center, Seattle, USA
16:25-16:45	Discussion	
<b>Special lecture: THE 15<sup>TH</sup> PLOTKIN LECTURE</b>		
16:45-16:55	<b>Introduction</b>	<b>Edwin Asturias</b> , Children's Hospital Colorado, USA
16:55-17:35	<b>Monkeypox</b>	<b>Adesola Yinka-Ogunleye</b> , Nigeria Centre for Disease Control, Abuja
17:35-17:55	Discussion	
17:55-18:05	Time for students to reflect personally on the learnings of the afternoon	

<b>THURSDAY 18 MAY 2023</b>		
<b>SESSION 10: VACCINES UNDER DEVELOPMENT</b>		<b>Chair: Edwin Asturias, Children's Hospital Colorado, USA</b>
08:30-08:55	<b>Vaccines against epidemic and orphan diseases: How new technologies can change vaccine development</b>	<b>Barney Graham, formerly Vaccine Research Center, NIAID, NIH, Bethesda, USA</b>
08:55-09:15	Discussion	
09:15-09:40	<b>The challenges of malaria vaccines</b>	<b>Mary Hamel, WHO, Geneva</b>
09:40-10:00	Discussion	
10:00-10:30	Break	
10:30-10:55	<b>Global challenges of cholera vaccines</b>	<b>Alejandro Cravioto, National Autonomous University of Mexico</b>
10:55-11:15	Discussion	
11:15-11:40	<b>HIV vaccines</b>	<b>Roger Le Grand, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases, France</b>
11:40-12:00	Discussion	
12:00-12:10	Time for students to reflect personally on the learnings of the morning	
12:10-13:10	Buffet lunch	
13:10-13:35	<b>Challenges and prospects for new tuberculosis vaccines</b>	<b>Helen McShane, University of Oxford, UK</b>
13:35-13:55	Discussion	
<b>SESSION 11: OUTBREAKS' CONTROL: ELIMINATION AND ERADICATION STRATEGIES</b>		<b>Chair: Kamel Senouci, University of Geneva</b>
13:55-14:20	<b>Immunization coverage gaps: overcoming the chronic challenges</b>	<b>Kate O'Brien, WHO, Geneva</b>
14:20-14:40	Discussion	
14:40-15:05	<b>Polio</b>	<b>Ananda Bandyopadhyay, Bill &amp; Melinda Gates Foundation, USA</b>
15:05-15:25	Discussion	
15:25-15:55	Break	
15:55-16:20	<b>Measles and rubella</b>	<b>Ann Lindstrand, WHO, Switzerland</b>
16:20-16:40	Discussion	
16:40-16:50	Time for students to reflect personally on the learnings of the afternoon	
18:30	<b>Departure to Château de Menthon Visit and special reception</b>	

## FRIDAY 19 MAY 2023

<b>SESSION 12: FACING THE MEDIA: WHAT THE VACCINOLOGIST SHOULD KNOW IN THE CONTEXT OF VACCINE HESITANCY AND ANTI-IMMUNIZATION LOBBY</b>		<b>Chair: Kamel Senouci</b> , University of Geneva
08:30-10:30	<b>Interactive session:</b> Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups	<b>Deborah Hall</b> , Broadcaster and Media Affairs Consultant, London, UK
10:30-10:50	Break	
10:50-13:00	Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups (continued)	
13:00-14:00	Lunch	
<b>SESSION 13: RECAP</b>		<b>Chair: Kamel Senouci</b> , University of Geneva
14:00:15:50	<b>Panel: Answers to questions from participants</b>	<b>Pieter Neels</b> , <b>Hanna Nohynek</b> , Finnish Institute for Health and Welfare, Finland (TBC), <b>Arnaud Didierlaurent</b> , University of Geneva, <b>Randa Hamadeh</b> , Immunization and Essential Drugs Program, Ministry of Public Health, Lebanon, <b>Ilesh Jani (VIA ZOOM)</b> , National Institute of Health, Mozambique, <b>Ann Lindstrand</b> , WHO Geneva, <b>Firdausi Qadri</b> , icddr,b.
15:50-16:30	<b>Highlights from ADVAC 2023</b>	<b>Romina Libster</b> , Fundación INFANT/ National Scientific and Technical Research Council/ Vanderbilt University
16:30-16:45	<b>Time for participants to complete the final evaluation (including commitment to change)</b>	
16:45	<b>Diploma ceremony, awarding of CME credits and closure of the Course</b>	<b>Alain Mérieux</b> , President, Fondation Mérieux and <b>Kamel Senouci</b> , Director, ADVAC, University of Geneva

<b>SESSION 1b - SPECIAL LECTURES FROM INDUSTRY</b>		
15:20-15:45	Role of LMIC vaccine industry for meeting global needs	<b>Manish Gautam</b> (via ZOOM), Executive Director, Serum Institute of India, Pune, India
15:45-16:05	Discussion	
16:05-16:30	Development and production of vaccines for global use: the role of vaccine industry	<b>Luis Jodar</b> , Senior Vice President and Chief Medical Officer, Vaccines, Pfizer Inc., USA
16:30-16:50	Discussion	